Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BioSpaceBridgeBio Pharma plans to file for approval in the third quarter.Rare DiseaseRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) BioSpace BridgeBio Pharma plans to file for approval in the third quarter. Rare Disease Read full story Post navigation Previous: Biogen trims Apellis pipeline and R&D team after $5.6bn takeoverNext: Zymeworks cuts deal to buy Theravance for $929m in cash Related Stories Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026 Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026 Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026
